These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29110838)

  • 1. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
    Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential therapeutic impact of CD13 expression in non-small cell lung cancer.
    Schmidt LH; Brand C; Stucke-Ring J; Schliemann C; Kessler T; Harrach S; Mohr M; Görlich D; Marra A; Hillejan L; Müller-Tidow C; Lenz G; Wardelmann E; Wiewrodt R; Berdel WE; Schwöppe C; Hartmann W
    PLoS One; 2017; 12(6):e0177146. PubMed ID: 28604784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-factor fusion proteins induce occlusion of tumor vessels.
    Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
    Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
    Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
    PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
    Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
    Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
    Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
    Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.
    Kessler T; Baumeier A; Brand C; Grau M; Angenendt L; Harrach S; Stalmann U; Schmidt LH; Gosheger G; Hardes J; Andreou D; Dreischalück J; Lenz G; Wardelmann E; Mesters RM; Schwöppe C; Berdel WE; Hartmann W; Schliemann C
    Transl Oncol; 2018 Dec; 11(6):1271-1282. PubMed ID: 30125801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
    Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
    Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
    Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
    Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
    Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
    Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.
    Brand C; Dencks S; Schmitz G; Mühlmeister M; Stypmann J; Ross R; Hintelmann H; Schliemann C; Müller-Tidow C; Mesters RM; Berdel WE; Schwöppe C
    J Ultrasound Med; 2015 Jul; 34(7):1227-36. PubMed ID: 26112625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
    Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.
    Schwöppe C; Zerbst C; Fröhlich M; Schliemann C; Kessler T; Liersch R; Overkamp L; Holtmeier R; Stypmann J; Dreiling A; König S; Höltke C; Lücke M; Müller-Tidow C; Mesters RM; Berdel WE
    J Med Chem; 2013 Mar; 56(6):2337-47. PubMed ID: 23496322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
    Seidi K; Jahanban-Esfahlan R; Monhemi H; Zare P; Minofar B; Daei Farshchi Adli A; Farajzadeh D; Behzadi R; Mesgari Abbasi M; Neubauer HA; Moriggl R; Zarghami N; Javaheri T
    Oncogene; 2018 Jul; 37(29):3967-3980. PubMed ID: 29662195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of (188)Re-labeled NGR-VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts.
    Ma W; Shao Y; Yang W; Li G; Zhang Y; Zhang M; Zuo C; Chen K; Wang J
    Tumour Biol; 2016 Jul; 37(7):9121-9. PubMed ID: 26768609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity.
    Corti A; Gasparri AM; Sacchi A; Colombo B; Monieri M; Rrapaj E; Ferreri AJM; Curnis F
    Mol Pharm; 2020 Oct; 17(10):3813-3824. PubMed ID: 32805112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.